- Market Capitalization, $K 30,038
- Shares Outstanding, K 22,756
- Annual Sales, $ 500 K
- Annual Income, $ -11,880 K
- 60-Month Beta 1.98
- Price/Sales 52.51
- Price/Cash Flow N/A
- Price/Book 1.91
|Period||Period Low||Period High||Performance|
| || |
-0.38 (-22.84%)since 01/17/20
| || |
-0.18 (-12.41%)since 11/19/19
| || |
-0.91 (-41.74%)since 02/19/19
Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy
Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.
Shares of Momenta (MNTA) rise 23.7% on pipeline updates.
Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.
Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.
Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.
aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.
-- Celsion's Chinese manufacturing partner, Hisun, to provide ThermoDox with an economically viable cost structure in China and other emerging markets.
Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share